Smartphone Technology to Alleviate Malignant Pain (STAMP)
The purpose of the study is to develop the STAMP app (Smartphone Technology to Alleviate Malignant Pain). This app will be used by patients with advanced cancer to track symptoms and receive tailored symptom management advice. This is a single arm pilot feasibility study of the application among patients with advanced cancer and chronic pain who are using opioids in the home setting. Patients will be asked to use the application for a four week period. Clinicians responsible for the patients' pain management will be asked to review alerts from the STAMP system and respond accordingly. The primary outcomes of the study relate to feasibility and acceptability.
Checked against the public recordLast updated Jun 5, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Health Services Research
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Dana-Farber Cancer Institute
- Interventions being studied
- Behavioral: Intervention Participants
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Patient Inclusion Criteria: * Patient is cared for within participating clinic (PC) * Age ≥21 * Diagnosed with locally advanced, metastatic solid tumor, or multiple myeloma being managed with palliative intent * Chronic pain related to cancer or cancer treatment, persisting or at least two weeks * Average pain rating of ≥4/10 currently, or at least one day within the past week * Active prescription for short and/or long acting opioids * Takes at least 1 opioid medication on most days * Own a compatible smartphone: * iPhone, have updated or willing to update it to the past 3 iOS version releases * Android flagship devices with more than 5% market share, last 2 android version releases Clinician Inclusion Criteria: * Physicians and mid-level providers practicing in participating clinics and caring for a patient on the study * Nurse Navigators working within participating clinics Exclusion Criteria: Patient Exclusion Criteria: * Cognitive impairment that would interfere with study participation, as judged by treating clinician * Inability to speak English * History of opioid use disorders * Enrolled in hospice * Currently hospitalized * Use of opioids not supported by STAMP * Pain primarily related to a recent surgery * Currently has or has had recurrent bowel obstructions * The following special populations are excluded: adults unable to consent, prisoners, and pregnant women. Clinician Exclusion Criteria: \- Unwilling to participate
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dana Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 5, 2023. Always confirm current availability with the study team.